Junevity Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
13
- Latest Deal Type
-
Early Stage VC
- Investors
-
10
Junevity General Information
Description
Operator of a biotechnology company intended to develop cell reset therapeutics for longevity. The company's platform uses large-scale human data and artificial intelligence to identify transcription factor targets and repress them with small interfering RNA therapeutics, enabling healthcare industry with medications for underserved and severe rewinding diseases of aging with novel transcription factor medicines.
Contact Information
Website
www.junevity.comCorporate Office
- 135 Mississippi Street
- San Francisco, CA 94107
- United States
Corporate Office
- 135 Mississippi Street
- San Francisco, CA 94107
- United States
Junevity Timeline
Junevity Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC | 30-Sep-2026 | Completed | Clinical Trials - General | |||
| 4. Seed Round | 22-May-2025 | Completed | Clinical Trials - General | |||
| 3. Seed Round | 10-Jul-2024 | Completed | Clinical Trials - General | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. University Spin-Out | 01-Jan-2023 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Junevity Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Junevity Patents
Junevity Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026136229-A1 | Methods and compositions for treating metabolic diseases | Pending | 16-Dec-2024 | ||
| WO-2025207883-A2 | Methods and compositions for treating metabolic diseases | Pending | 27-Mar-2024 | ||
| WO-2025207883-A3 | Methods and compositions for treating metabolic diseases | Pending | 27-Mar-2024 | C12N15/113 |
Junevity Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Junevity Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amorepacific Ventures | Corporate Venture Capital | Minority | ||
| Godfrey Capital | Family Office | Minority | ||
| Goldcrest Capital | Venture Capital | Minority | ||
| Venture Science | Growth/Expansion | Minority | ||
| Angel (individual) | Minority |
Junevity FAQs
-
When was Junevity founded?
Junevity was founded in 2023.
-
Where is Junevity headquartered?
Junevity is headquartered in San Francisco, CA.
-
What is the size of Junevity?
Junevity has 13 total employees.
-
What industry is Junevity in?
Junevity’s primary industry is Biotechnology.
-
Is Junevity a private or public company?
Junevity is a Private company.
-
What is Junevity’s current revenue?
The current revenue for Junevity is .
-
How much funding has Junevity raised over time?
Junevity has raised $20M.
-
Who are Junevity’s investors?
Amorepacific Ventures, Godfrey Capital, Goldcrest Capital, Venture Science, and are 5 of 10 investors who have invested in Junevity.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
